Found 5 resultsAuthor [ Title] Type Year
Filters: Author is Francis, D [Clear All Filters]
A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses, 16(9), 907-19. presented at the 2000 Jun 10. doi:10.1089/08892220050042846. (2000).
A Phase II study of two HIV-1 envelope vaccines comparing their immunogenicity in populations at risk for acquiring HIV-1 infection. AIDS Res HumRetroviruses, 16, 907-19. presented at the 2000.. (2000).
Risk Behaviour and Time as Covariates for Efficacy of the HIV Vaccine Regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: A Post-Hoc Analysis of the Thai Phase 3 Efficacy Trial RV 144. Lancet Inf Dis, 12, 531-537. presented at the 07/2012. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22652344. (2012).
Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand. PLoS One, 6, e27837. presented at the 12/2011. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22205930. (2011).
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. N Engl J Med, 361, 2209-2220. presented at the 12/2009. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/19843557. (2009).